SBR consortium holds its final meeting
20 Aug 25
On 21st November 2024, the SBR consortium gathered online for its final meeting, marking the conclusion of more than five
On 21st November 2024, the SBR consortium gathered online for its final meeting, marking the conclusion of more than five
El projecte va obtenir un finançament de 985.000 € per part de l’Agència Estatal d’Investigació i reuneix un consorci de
Osteoarticular osteoarthritis is a chronic degenerative disease that affects the joints, particularly in older individuals, negatively impacting their quality of
On February 14, 2025, the kick-off meeting (KOM) of the VAGINEF project took place at the Vall d’Hebron Research Institute
The biopharmaceutical company ONCOMATRYX Biopharma and Leitat are collaborating in the NEXTOM project, which aims to develop new Antibody Drug
In an era where science and technology play a fundamental role in the well-being of future generations, the GUTBABI project
El proyecto ONCO_IVD tiene como objetivo el diseño y la validación de un nuevo test de cribado para la detección
The TRiAnkle project consortium, comprising 12 dedicated partners, gathered on 11–12 December 2024 at Fraunhofer IGB in Stuttgart, Germany, to
Development of a new targeted therapy for the treatment of metabolically adapted tumors Abstract: The main goal of this project
On 13th-14th June 2024, the PrecisionTox project consortium, consisting of 15 partners, gathered in Flagey, Brussels, Belgium, to advance the
The consortium of the StretchBio project, consisting of 5 partners, gathered on April 24, 2024, in an online meeting to
Development of Next-Generation ADCs (Antibody-Drug Conjugates) for the Treatment of Invasive Tumours Abstract: The NEXTOM project aims to develop innovative
CANTABRIA LABS y Leitat han unido fuerzas en el proyecto UPCOSMETIC. Este ambicioso proyecto tiene como objetivo principal explorar nuevas
Las alergias alimenticias son un problema de salud significativo que afecta a más de 17 millones de personas en Europa,
Las enfermedades neurológicas, en su mayoría, tienen su origen en alteraciones en la expresión génica, regulada por mecanismos epigenéticos dentro
El proyecto MEDICSEN ofrece una opción de tratamiento no invasivo para enfermedades crónicas como la diabetes y algunas enfermedades autoinmunes,
Phone. (+34) 937 882 300
